On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...

Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

欢迎关注凯莱英药闻近期，诺和诺德在基因编辑领域进一步加码；首先是在2024年6月，公司以最高4000万美元收购2seventy bio的A ...

据了解，2seventy ...

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...

据了解，2seventy bio和其合作伙伴百时美施贵宝宣布，将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究，旨在评估Abecma与来那度胺联合治疗，以及来那度胺单药治疗的效果。两家公司表示，这一决定是在对该研究的商业理由进行彻底审查后做出的。

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...

(Reuters) - 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...